Related Experiment Video
Updated: Nov 4, 2025

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
Published on: August 20, 2019
Adaption of the OMOP CDM for Rare Diseases
Michele Zoch1, Christian Gierschner1, Yuan Peng1
1Institute for Medical Informatics and Biometry at Carl Gustav Carus Faculty of Medicine at Technische Universität Dresden, Germany.
Abstract:
The OMOP Common Data Model (OMOP CDM) is an option to store patient data and to use these in an international context. Up to now, rare diseases can only be partly described in OMOP CDM. Therefore, it is necessary to investigate which special features in the context of rare diseases (e.g. terminologies) have to be considered, how these can be included in OMOP CDM and how physicians can use the data. An interdisciplinary team developed (1) a Transition Database for Rare Diseases by mapping Orpha Code, Alpha ID, SNOMED, ICD-10-GM, ICD-10-WHO and OMOP-conform concepts; and (2) a Rare Diseases Dashboard for physicians of a German Center of Rare Diseases by using methods of user-centered design. This demonstrated how OMOP CDM can be flexibly extended for different medical issues by using independent tools for mappings and visualization. Thereby, the adaption of OMOP CDM allows for international collaboration, enables (distributed) analysis of patient data and thus it can improve the care of people with rare diseases.
Related Concept Videos
Methods of Documentation II: POMR
Genomics
Model Approaches for Pharmacokinetic Data: Physiological Models
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Analysis of Population Pharmacokinetic Data

